Viracta Therapeutics, Inc.
METHODS OF TREATING VIRALLY ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS
Last updated:
Abstract:
Described herein are certain dosing schedules and amounts that effectively prevent and manage side effects associated with histone deacetylase inhibitor (HDACi) treatment. Optionally, these schedules and dosing regimens include treatment with an antiviral agent.
Status:
Application
Type:
Utility
Filling date:
8 Jul 2020
Issue date:
3 Dec 2020